- Home
- PDM vs NKTR Comparison
PDM vs NKTR Comparison
Compare PDM & NKTR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PDM | NKTR |
|---|---|---|
| Founded | 1997 | 1990 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Building operators | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.3B |
| IPO Year | 1997 | 1996 |
Fundamental Metrics
Financial Performance| Metric | PDM | NKTR |
|---|---|---|
| Price | $9.96 | $37.24 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 4 | 15 |
| Target Price | $10.75 | ★ $133.08 |
| AVG Volume (30 Days) | ★ 1.3M | 599.5K |
| Earning Date | 10-26-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $564,994,000.00 | $307,711,000.00 |
| Revenue This Year | $3.70 | N/A |
| Revenue Next Year | $1.32 | $27.72 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 86.00 |
| 52 Week Low | $6.32 | $33.40 |
| 52 Week High | $10.23 | $109.00 |
Technical Indicators
Market Signals| Indicator | PDM | NKTR |
|---|---|---|
| Relative Strength Index (RSI) | 58.70 | 38.33 |
| Support Level | $9.24 | $35.68 |
| Resistance Level | $10.02 | $40.12 |
| Average True Range (ATR) | 0.27 | 1.55 |
| MACD | 0.04 | 0.90 |
| Stochastic Oscillator | 75.11 | 37.77 |
Price Performance
Historical ComparisonAbout PDM Piedmont Office Realty Trust Inc.
Piedmont Realty Trust Inc is a fully integrated, self-managed real estate investment company focused on delivering an exceptional office environment. As an owner, manager, developer and operator of 16 MM SF of Class A properties across U.S. Sunbelt markets, Piedmont Realty Trust is known for its hospitality-driven approach and commitment to transforming buildings into Piedmont PLACEs that enhance each client's workplace experience.
About NKTR Nektar Therapeutics
Nektar Therapeutics is a clinical-stage, research-based biopharmaceutical company headquartered in San Francisco, California, and incorporated in Delaware, focused on discovering and developing medicines in the field of immunotherapy. The Company directs its efforts toward creating immunomodulatory agents that selectively induce, amplify, attenuate, or prevent immune responses to achieve desired therapeutic outcomes. Its pipeline of clinical-stage and preclinical-stage immunomodulatory agents targets the treatment of autoimmune diseases, including rezpegaldesleukin, NKTR-0165, NKTR-0166, and NKTR-422, as well as cancer, including NKTR-255.